Bioton S.A. (WAR:BIO) — Market Cap & Net Worth
Market Cap & Net Worth: Bioton S.A. (BIO)
Bioton S.A. (WAR:BIO) has a market capitalization of $98.54 Million (zł358.05 Million) as of May 3, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #19240 globally and #153 in its home market, demonstrating a -0.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioton S.A.'s stock price zł4.17 by its total outstanding shares 85864200 (85.86 Million). Analyse Bioton S.A. cash flow conversion to see how efficiently the company converts income to cash.
Bioton S.A. Market Cap History: 2015 to 2026
Bioton S.A.'s market capitalization history from 2015 to 2026. Data shows change from $281.92 Million to $98.54 Million (-8.47% CAGR).
Bioton S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioton S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.33x
Bioton S.A.'s market cap is 0.33 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $281.92 Million | $404.41 Million | -$522.86 Million | 0.70x | N/A |
| 2016 | $193.07 Million | $277.61 Million | -$28.57 Million | 0.70x | N/A |
| 2017 | $82.47 Million | $361.65 Million | -$7.27 Million | 0.23x | N/A |
| 2018 | $119.57 Million | $241.17 Million | $26.27 Million | 0.50x | 4.55x |
| 2019 | $89.80 Million | $202.03 Million | -$126.69 Million | 0.44x | N/A |
| 2020 | $102.32 Million | $221.79 Million | $33.92 Million | 0.46x | 3.02x |
| 2021 | $98.90 Million | $163.03 Million | $2.88 Million | 0.61x | 34.32x |
| 2022 | $79.64 Million | $233.16 Million | $1.42 Million | 0.34x | 56.04x |
| 2023 | $84.36 Million | $181.64 Million | $2.27 Million | 0.46x | 37.08x |
| 2024 | $68.18 Million | $207.76 Million | -$15.66 Million | 0.33x | N/A |
Competitor Companies of BIO by Market Capitalization
Companies near Bioton S.A. in the global market cap rankings as of May 3, 2026.
Key companies related to Bioton S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Bioton S.A. Historical Marketcap From 2015 to 2026
Between 2015 and today, Bioton S.A.'s market cap moved from $281.92 Million to $ 98.54 Million, with a yearly change of -8.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł98.54 Million | +8.03% |
| 2025 | zł91.22 Million | +33.80% |
| 2024 | zł68.18 Million | -19.19% |
| 2023 | zł84.36 Million | +5.93% |
| 2022 | zł79.64 Million | -19.47% |
| 2021 | zł98.90 Million | -3.35% |
| 2020 | zł102.32 Million | +13.95% |
| 2019 | zł89.80 Million | -24.90% |
| 2018 | zł119.57 Million | +44.99% |
| 2017 | zł82.47 Million | -57.28% |
| 2016 | zł193.07 Million | -31.52% |
| 2015 | zł281.92 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Bioton S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $98.54 Million USD |
| MoneyControl | $98.54 Million USD |
| MarketWatch | $98.54 Million USD |
| marketcap.company | $98.54 Million USD |
| Reuters | $98.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bioton S.A.
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes m… Read more